Tamoxifen therapy for breast cancer and endometrial cancer risk

Journal of the National Cancer Institute

Volumn 91, Issue 19, 1999, Pages 1654-1662

  Bernstein, Leslie ^a,g   Deapen, Dennis ^a   Cerhan, James R ^b   Schwartz, Stephen M ^c   Liff, Jonathan ^d   McGann Maloney, Erin ^a   Perlman, Jeffrey A ^e   Ford, Leslie ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EMORY UNIVERSITY   (United States)

^e U S PUBLIC HEALTH SERVICE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0033530255     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.19.1654     Document Type: Article

References (35)

1. Jordan VC. Tamoxifen: the herald of a new era of preventive therapeutics [editorial]. J Natl Cancer Inst 1997;89:747-9.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351: 1451-67.
4. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in the prevention of breast cancer. J Natl Cancer Inst 1991;83: 1450-9.
5. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
6. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7.
7. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
8. Assikis VJ, Jordan VC. Risks and benefits of tamoxifen therapy. Oncology (Huntingt) 1997;11(Suppl 1):21-3.
9. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69: 237-8.
10. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
11. Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88:832-4.
12. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
13. Sasco AJ, Chaplain G, Amoros E, Saez S. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 1996;7:9-13.
14. Mignotte H, Lassett C, Bonadona V, Lesur A, Luporsi E, Rodier JF, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998;78:325-30.
15. International Agency for Research on Cancer (IARC), editor. Tamoxifen. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 66. Lyon (France): IARC; 1996. p. 253-365.
16. Grady G, Ernster VL. Endometrial cancer. In: Schottenfeld D, Fraumeni J Jr, editors. Cancer epidemiology and prevention. 2nd ed. New York (NY): Saunders; 1996. p. 1058-89.
17. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1 - The analysis of case-control studies. IARC Sci Publ 1980;32:192-278.
18. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
19. Fromson JM, Sharp DS. The selective uptake of tamoxifen by human uterine tissue. J Obstet Gynaecol Br Commonw 1974;81:321-3.
20. Groom GV, Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 1976;70:421-8.
21. Sherman BM, Chapler FK, Crickard K, Wycoff D. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979;64:398-404.
22. Lonning PE, Johannessen DC, Lien EA, Ekse D, Fotsis T, Adlercreutz H. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients [published erratum appears in J Steroid Biochem Mol Biol 1996;57:149]. J Steroid Biochem Molec Biol 1995;52:491-6.
23. Zaino RJ, Satyasaroop PG, Mortel R. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res 1985;45: 539-41.
24. Gorodeski GI, Barry R, Lunenfeld B, Geier A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fertil Steril 1992;57:320-7.
25. Boccardo F, Bruzzi P, Rubagotti A, Nicolo GU, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981;38:281-5.
26. Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, et al. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984;70:61-8.
27. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.
28. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81(Pt 1):660-4.
29. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998; 91:40-4.
30. Elkas J, Gray K, Howard L, Petit N, Pohl J, Armstrong A. The effects of tamoxifen on endometrial insulin-like growth factor-I expression. Obstet Gynecol 1998;91:45-50.
31. Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxsf) 1974;3:69-96.
32. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995;87:1359-64.
33. MacMahon B. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol 1997;24(Suppl 1):S1-122-S1-39.
34. Horwitz RI, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978;199: 1089-94.
35. Horwitz RI, Feinstein AR. Estrogens and endometrial cancer. Responses to arguments and current status of an epidemiologic controversy. Am J Med 1986;81:503-7.